Keytruda

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless...

After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after ending 2023 with good news from its combined treatment with Moderna Inc (NASDAQ: MRNA) in...

CEOs of Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) defended the high prices of their drugs as they were grilled by the Senate Health Committee, led by Senator Bernie Sanders who submitted a report blasting the extravagant cost of three drugs. "Merck...

As Merck & Co Inc (NYSE:MRK) moves closer to reporting its fourth-quarter results in three days, its stock is validating investor confidence. While Merck stock is up 20% since Nov. 28, a technical signal indicates the rally isn’t over yet. Merck would be reporting on Feb. 1 before market...

Pharmaceutical company Merck & Company (NYSE: MRK) reports second quarter financial results before market open Tuesday. After being one of the 15 Dow Jones component stocks that traded higher in the first half of 2023, investors now see the stock down year-to-date. Here’s a look at the...

A biotechnology company using selective tranlsation regulation inhibitors to treat cancer is going public in a SPAC deal.  The SPAC Deal: eFFECTOR Therapeutics will merge with Locust Walk Acquisition Corp (NASDAQ: LWAC) in a deal bringing a next generation oncology company public. The deal...

Merck & Co., Inc’s (NYSE: MRK) internal pipeline seems underappreciated by the market, and the loss of exclusivity of its cancer immunology drug Keytruda appears priced in, according to Goldman Sachs. The Merck Analyst: Terence Flynn upgraded Merck from Neutral to Buy and raised the price...

Merck & Co., Inc. (NYSE: MRK) shares came under pressure in Tuesday's session after the pharma company lowered its full-year guidance. The Merck Analysts Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $107 price target. SVB Leerink analyst Daina Graybosch...

Merck & Co., Inc.'s (NYSE: MRK) shares have underperformed the broader market and the pharma sector per se, and one among the two factors that have led to weakness is soft sales for its wonder cancer drug Keytruda in the fourth quarter. The Merck Analyst JPMorgan analyst Chris Schott...

Shares of the thinly traded, nano-cap biotech PDS Biotechnology Corp (NASDAQ: PDSB) were rallying strongly Thursday on above-average volume. What Happened  PDS, which engages in the development of multifunctional immunotherapic products, announced a modified clinical trial...

Merck & Co., Inc. (NYSE: MRK) wonder cancer immunotherapy has managed to notch sever clinical and regulatory milestones this year. What Happened Merck announced Monday the Phase 3 KEYNOTE-522 study that is evaluating its Keytruda in combination with chemotherapy to treat triple-negative breast...

The FDA approval machinery worked overtime in May, with several new labelings, original approvals and new molecule approvals coming through in the month. The month saw the approval of two new molecular entities, or NMEs: Novartis AG (NYSE: NVS)'s Piqray in combination with fulvestrant to treat...

Two big pharma titans are battling for supremacy in the field of oncology immunotherapy. From the looks of it, Kenilworth, New Jersey-based Merck & Co., Inc. (NYSE: MRK) may have the upper hand over Bristol-Myers Squibb Co (NYSE: BMY). Before poring over the specifics, here's what...

Shares of small-cap biotech Iovance Biotherapeutics Inc (NASDAQ: IOVA) were making a strong upward move Thursday on more than 10 times their average volume.  Iovance announced multiple updates in conjunction with online abstracts made available ahead of presentations at the...

Biotech stocks came under selling pressure in March, but much of the FDA decisions of the month produced positive results. PDUFA dates are deadlines for the FDA to review new drugs. The FDA is normally given 10 months to review new drugs. If a drug is selected for priority review, the FDA is...